Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Aerovate Therapeutics Inc (AVTE)

Aerovate Therapeutics Inc (AVTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) Globe Newswire - Mon May 16, 2022

AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the...

AVTE : 2.01 (+4.69%)
Aerovate Therapeutics Announces First Quarter 2022 Financial Results Globe Newswire - Mon May 16, 2022

WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on...

AVTE : 2.01 (+4.69%)
Aerovate Therapeutics Announces Full-Year 2021 Financial Results Globe Newswire - Wed Mar 30, 2022

Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021Received FDA guidance in April 2021...

AVTE : 2.01 (+4.69%)
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension Globe Newswire - Wed Dec 15, 2021

WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on...

AVTE : 2.01 (+4.69%)
Aerovate Therapeutics Announces Third Quarter 2021 Financial Results Globe Newswire - Mon Nov 15, 2021

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on...

AVTE : 2.01 (+4.69%)
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index Globe NewsWire - Fri Sep 17, 2021

WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.  (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...

AVTE : 2.01 (+4.69%)
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results Globe NewsWire - Mon Aug 16, 2021

WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.    (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...

AVTE : 2.01 (+4.69%)
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors Globe NewsWire - Mon Jul 19, 2021

BOSTON, July 19, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients...

AVTE : 2.01 (+4.69%)
Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares Globe NewsWire - Fri Jul 2, 2021

BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients...

AVTE : 2.01 (+4.69%)
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering Globe NewsWire - Tue Jun 29, 2021

BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients...

AVTE : 2.01 (+4.69%)

Barchart Exclusives

Tesla Stock Forecast Post-Q2 Earnings: 'Present Imperfect, Future Uncertain' Barchart - 31 minutes ago
Tesla stock crashed following its Q2 earnings earlier this week. Here are the key takeaways from the report, and the forecast for the company amid a challenging macro environment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot